Axon Clinical Research

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Atopic dermatitis (eczema)7 trials
• Vitiligo1 trial

Phase

• Phase 35 trials
• Phase 23 trials

Status

• Completed6 trials
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• Eli Lilly and Company3 trials
• Amgen1 trial
• BioMimetix JV, LLC1 trial
• Incyte Corporation1 trial
• Insmed Incorporated1 trial
• and 1 more

Running trials

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo

  NCT06548360· Phase 3· Incyte Corporation· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Vitiligo1 recruiting

Closed trials

• Completed

  Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)

  NCT06101823· Phase 2· Insmed Incorporated· Source

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Amgen· Source

• Completed

  A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

  NCT05372419· Phase 3· Eli Lilly and Company· Source

• Terminated

  A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis

  NCT05491447· Phase 2· BioMimetix JV, LLC· Source

• Completed

  A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

  NCT05369403· Phase 3· Eli Lilly and Company· Source

• Completed

  Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)

  NCT05469464· Phase 2· UNION therapeutics· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Eli Lilly and Company· Source